Drug
Vk2809
Vk2809: highest development phase Phase 2, developed by Viking Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Viking Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| VK2809 NCT02927184 | Phase 2 | Hyperlipidemia |
| VK2809 NCT04173065 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
Latest
No recent events.
Follow Vk2809 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.